ANXA1 is linked to sensitivity to TKIs[156], and in clear cell renal cancer (CCRC), YTHDC1, a reader of the m6A modification[157], interacts with ANXA1 mRNA via the m6A modification, reducing its stability, thereby inactivating the MAPK signaling pathway and rendering CCRC cells sensitive to TKIs[158]. The gene discussed is ANXA1; the disease is clear cell renal carcinoma.